Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Vasopressin
Drug ID BADD_D02339
Description Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids.[A228013] Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V1 and V2 cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for more than five decades for varying conditions, including variceal bleeding, diabetes insipidus, and, more recently, vasodilatory shock.[A228013] It is currently marketed under the trademark VASOSTRICT® by PAR Pharmaceuticals.[L31413]
Indications and Usage Vasopressin is indicated to increase blood pressure in adults in vasodilatory shock refractory to the application of fluids and catecholamines.[L31413]
Marketing Status approved
ATC Code Not Available
DrugBank ID DB00067
KEGG ID D00101
MeSH ID D014667
PubChem ID 644077
TTD Drug ID D0N4OW
NDC Product Code 35207-0005; 41701-008; 55150-371; 71872-7014; 52416-127; 51662-1607; 0548-9701; 42023-220; 0517-1030; 42023-164; 42023-190; 42023-237; 71872-7264; 14799-3001; 42367-570; 51662-1623; 0517-1020; 51662-1314; 65219-039; 63586-0004; 42023-219; 55150-370; 70121-1642; 63323-930; 43598-085; 59651-242
UNII Y4907O6MFD
Synonyms Vasopressins | Antidiuretic Hormones | Antidiuretic Hormone | Hormone, Antidiuretic | beta-Hypophamine | beta Hypophamine | Pitressin | Vasopressin (USP) | Vasopressin
Chemical Information
Molecular Formula C46H65N15O12S2
CAS Registry Number 113-79-1
SMILES C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N) CC3=CC=CC=C3)CC4=CC=C(C=C4)O)N)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Angina pectoris02.02.02.002; 24.04.04.002--
Arrhythmia02.03.02.001---
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cardiac output decreased13.14.02.001---
Gangrene11.02.01.003; 23.06.06.001; 24.04.05.003---
Headache17.14.01.001--
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hypersensitivity10.01.03.003--
Myocardial ischaemia02.02.02.008; 24.04.04.010---
Nausea07.01.07.001--
Pallor08.01.03.032; 23.03.03.031; 24.03.04.001---
Polyuria20.02.03.002---
Shock24.06.02.002---
Tremor17.01.06.002--
Urticaria10.01.06.001; 23.04.02.001--
Vasoconstriction23.06.05.007; 24.04.03.008---
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Water intoxication05.03.03.003; 14.05.06.004; 19.07.03.004---
Pneumatosis08.01.03.044---
Urine output increased13.13.03.002---
The 1th Page    1    Total 1 Pages